Reducing irinotecan‐associated diarrhea in children
- 14 June 2007
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (2), 201-207
- https://doi.org/10.1002/pbc.21280
Abstract
Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan. Pediatr Blood Cancer 2008; 50:201–207.Keywords
This publication has 73 references indexed in Scilit:
- Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study GroupJournal of Clinical Oncology, 2007
- Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid TumorsJournal of Clinical Oncology, 2006
- Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal CancerOncology, 2005
- Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA ratsInternational Journal of Cancer, 2005
- A phase I study of irinotecan administered on a weekly schedule in pediatric patientsPediatric Blood & Cancer, 2005
- New approaches to prevent intestinal toxicity of irinotecan-based regimensCancer Treatment Reviews, 2004
- Oral RDP58 Allows CPT-11 Dose Intensification for Enhanced Tumor Response by Decreasing Gastrointestinal ToxicityClinical Cancer Research, 2004
- A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid TumorsJournal of Clinical Oncology, 2003
- Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38) by the Human UDP-Glucuronosyltransferases Encoded at the UGT1 LocusBiochemical and Biophysical Research Communications, 1999
- Irinotecan (CPT-11): pharmacology and clinical applicationsCritical Reviews in Oncology/Hematology, 1996